Early Detection of Amyloid Plaques in Mouse Models of Alzheimer’s Disease by PET with <sup>18</sup>F-Hydroxy Quinoline

Research Article

Austin J Clin Neurol 2015;2(8): 1065.

Early Detection of Amyloid Plaques in Mouse Models of Alzheimer’s Disease by PET with 18F-Hydroxy Quinoline

Kulkarni PV¹*, Alhasan M², Chiguru S¹, Arora V¹, Slavine N¹, Hao G¹, Sun X¹, Antich P¹ and Bonte FJ¹

¹Department of Radiology, UT Southwestern Medical Center, USA

²Department of Allied Medical Sciences, Jordan University of Science and Technology, Jordan

*Corresponding author: Kulkarni PV, Department of Radiology, UT Southwestern Medical Center, 5323 Harry Hines Blvd Dallas, USA

Received: April 14, 2015; Accepted: June 16, 2015; Published: June 28, 2015


Goal of the study was to evaluate 18F-(8-hydroxy) quinoline (18F-HOQ) by PET in transgenic (Tg) animal models of Alzheimer’s disease (AD). Five groups of mice (n=4 per group) were used; control (WT, 12 mo), APP/PS Tg mice (4, 6, and 12 mo) and APOE4 Tg mice (12 mo). 18F-HOQ was prepared as previously reported by us. Animals were imaged in a PET/CT scanner for 30 minutes immediately after intravenous injection of the tracer and SUV values for various brain regions determined. After imaging, animal brain sections were stained and amyloid plaque burden measured. Cortex, olfactory bulbs and hippocampus had higher activity compared to cerebellum and were significantly higher (p<0.05) in APP/PS1 Tg mice compared to WT or APOE4 mice. Only APP/PS1 mice brain sections were positive for Aβ. Tracer uptake by PET correlated with plaque density measured by histopathology. Plaque density increased with age. Differences in brain uptake by PET could be observed at an early age (4 mo) only in APP/PS1 mice. F-18 HOQ may be useful in monitoring the progression of Aβ plaque deposition in suitable AD animal models by PET and in assessing efficacy of therapeutic agents aimed at reduction of amyloid plaque burden.

Keywords: Alzheimer’s disease; Transgenic animals; Plaques; PET/CTimaging


Alzheimer’s disease (AD) is the most common cause of dementia. AD is a neurodegenerative disorder of enormous socioeconomic burden [1]. It represents animmuno-inflammatory reaction resulting in the activation of the immune system in response to aberrant proteins located in the brain and leading to neurotoxicity [2]. Neurodegenerative disorders are defined as progressive loss of neurons. The pathologic hallmarks of AD are extracellular beta amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) [3]. The amyloid cascade hypothesis has explained the mechanism of the disease based on the presence and the deposition of the amyloid plaques [4]. The abnormal function of these intracellular and extracellular proteins results in death of neurons [5]. Noninvasive detection of deposition of Aβ plaques is important in understanding the pathology of early AD. The development of radiopharmaceuticals for medical imaging with positron emission tomography (PET) may provide an ideal non-invasive methodology to enable early diagnosis, monitor disease progression, differential diagnosis, and evaluate drug therapies of patients with AD and related dementias [6-8]. A number of recent articles have reviewed the progress in development of imaging agents targeting beta amyloid [9-13].

A number of molecules including derivatives of Thioflavin and Congo red, labeled with carbon-11 (11C; t1/2 = 20.4 min) and fluorine-18 (18F; t1/2 = 109.7 min) have been synthesized and investigated for imaging amyloid plaques and tangles with promising results [14- 18]. Fluorine-18 labeled agents are more desirable than those labeled with carbon-11 because of relatively longer half-life affording longer radio-synthesis, imaging protocols and option for supply by a commercial manufacturer to imaging sites without a cyclotron and/ or radiochemistry laboratories. Majority of radiotracers for imaging AD are based on Congo red or thioflavin derivatives with affinity for amyloid Aβ plaque deposits. The most widely used radiotracer for imaging AD is a labeled thioflavin analog, N-methyl-[11C]2- (4’-methylaminophenyl)-6-hydroxybenzothiazole (referred to as Pittsburgh Compound-B or PiB), [15, 17] with recent efforts directed towards labeled styrylpyridine and stilbene derivatives [18].

Among the transitional elements iron, zinc and copper are essential to human health. However they also have shown to be involved in AD. Copper overload has been associated with mental decline [19] and particularly AD development [20, 21]. As the most abundant trace metal in the brain, zinc is tightly associated with numerous proteins. Role of zinc and copper in neurodegenerative process have been extensively reviewed [22, 23]. Deposition of amyloid plaque protein is intimately associated with the increased levels of transition metal ions such as Cu2+ and Zn2+ [24-30]. High concentration of zinc (up to 1 mM) have been found within amyloid plaques [24], which is thought to have been released from glutamatergic synapses [25]. Hydroxyquinoline (HOQ) and its derivatives are under investigation for therapeutic applications based on extraction of metal ions and disaggregation of plaque [31-38]. Kinetically slow re extraction of Zn could be useful potentially in imaging amyloid plaque using transition metal chelating agents. Opazo et al utilized this strategy in exploring radio iodinated clioquinol (CQ) as a biomarker for β– amyloid in human subjects [39]. Using autoradiography imaging, 125ICQ was demonstrated to be specific for imaging β–amyloid plaque in histological samples. However, a large portion of administered 125I-CQ was taken up by liver and metabolized and less than 1% of this activity was taken up by brain. Further, it can undergo facile de– iodination in vivo. Thus, [125/124I] CQ might not be ideal for diagnostic imaging of AD. We designed polybutylcyanoacrylate nanoparticles with incorporated radio ligands and amyloid affinity agents that are attracted to Aβ protein. We evaluated nanoparticulate radio labeled quinolone to detect amyloid plaques in mouse models of AD [40].

A small, blood brain barrier (BBB) permeating, stable and non– polar 18F labeled HOQ that forms a rapid and reversible ternary complex with Zn–Aβ fibrils could be useful for imaging amyloid plaques with high specificity. Previously we reported the synthesis of 18F–2–fluoro–8–hydroxy quinoline (18F-HOQ) and preliminary evaluation in imaging of AD plaques in APP/PS1 transgenic mice [41, 42]. Here we report the evaluation the tracer in PET imaging of APP/PS1 and APOE4 transgenic mice of different ages, also assed the possibility of analyzing the regional tracer uptake and washout kinetics in mice brain similar to other plaque imaging agents in human brain. Uptake of tracer in mice brain was measured by PET/ CT imaging and correlated with the amyloid burden by histology.

Although current transgenic (Tg) animal models obviously do not manifest all clinical and pathological aspects of AD, nonetheless they are useful in testing of novel intervention strategies and imaging agents.


Animal models

There are number of animal models of AD and may not truly represent the human AD. However, they are valuable tools in evaluating experimental imaging and therapeutic agents. The animal experimental protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of UT Southwestern Medical Center. Here in our study we used double (APP/PS1) double transgenic and APOE4 transgenic mice in evaluating fluorine-18 labeled quinolone. Double transgenic mice with double mutation (APP/PS1) for Alzheimer’s disease were used (Strain: B6C3–Tg) (APPswe, PSEN1dE9)85Dbo/J). This particular model corresponds to a form of early onset of disease and expresses mutant human presenalin 1 (DeltaE9) and a chimeric mouse/human amyloid precursor protein (APPswe) and APOE4 Tg mice representing late onset of AD [43-45]. APP transgenic mice were obtained from Dr. Qu laboratory at UT Southwestern and have been well characterized by gene typing [46].Three groups of mice (n=4 per group) were used for PET imaging studies: 1. control (WT), 2. Tg mice, APP/PS1, (strain B6C3-Tg, APPswe, PSEN1 dE9) and 3. APOE4 Tg mice (Taconic, #1549, C57BL/6), ages 11-12 months. Frozen brain sections of APP/ PS1 Tg and control (WT) mice were incubated with 18F-HOQ (50μCi/ mL), washed and exposed to Phosphor Imaging Plate® for 2 h and images quantified as digital light units (DLU). Autoradiography, histology and in vitro studies were reported in details somewhere else [42].

Small animal PET/CT imaging

Small animal PET/CT imaging studies were performed using a Siemens Inveon® Multimodality PET/CT system (Siemens Medical Solutions Inc., Knoxville, TN, USA). Ten minutes prior to imaging, the animals were anesthetized using 3% Isoflurane at room temperature until stable vital signs were established. Once the animal was sedated, the animal was placed onto the imaging bed under 2% Isoflurane anesthesia for the duration of the imaging. The micro CT imaging was acquired at 80kV and 500 μA with a focal spot of 58μm. The PET images were acquired directly following the acquisition of CT data. Radiotracer (50-90 μCi) was injected intravenously via the tail vein. Immediately following the injection, a 20-30 minute dynamic scan was performed. PET images were reconstructed using Fourier Rebinning and Ordered Subsets Expectation Maximization 3D algorithm with dynamic framing every 60 seconds. Reconstructed images were fused and analyzed using Inveon® Research Workplace (IRW) software.

F-18 quinoline (18F-HOQ) was prepared as previously reported by us; reacting 8-benzyloxy-2-chloroquinoline with K222 and F-18 in DMSO and purified by HPLC [5, 6]. TgAD and WT mice (n=4 per group), were scanned in a Siemens Inveon® PET/CT scanner for 30 minutes immediately following i.v. injection. SUV values for various brain regions were determined using AMIDE® software and an MRI 3D mouse brain atlas. After imaging studies, animal brains were taken out, fixed and brain tissue sections were stained with an antibody specific to Aβ and plaque burden measured with Image J ® software.

PET/CT analysis using MRI brain atlas

PET/CT images analyzed using AMIDE software and a 3D mouse brain atlas. PET images (voxel volume: 0.9×0.9×0.8 mm) were overlaid on the CT images (voxel volume: 0.2×0.2×0.2 mm). The registration of the images was performed by identifying three anatomical regions (e.g. heart, kidneys and the brain) on both images. The brain region was segmented based on a 3D mouse brain atlas (voxel volume: 0.06×0.06×0.06 mm) into distinct areas where the plaques are mostly found.

These areas include olfactory bulb, cerebral cortex, hippocampus and to lesser extent cerebellum [14-18]. 3D ROIs were selected to cover these regions in each plane including axial, coronal and sagittal plane (Figure 1). The activity in each region was quantified using standardized uptake value (SUV):